email article
Birth centers were associated with a higher risk of adverse infant outcomes, including neonatal death, according to a retrospective cohort study.
Neonatal death was more than four times more likely to occur in a freestanding birth center than in a hospital setting when delivered by a midwife (aOR 4.44, 95% CI 2.97-6.64), reported Amos Grünebaum, MD, of the Lenox Hill Hospital and Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York, and colleagues.
First-time mothers had an even greater risk, being eight times more likely to experience neonatal death in birth centers (aOR 8.00, 95% 5.56-14.03), Grünebaum said in a presentation at the American College of Obstetricians and Gynecologists (ACOG) virtual meeting.
FDA, CDC support resuming use of J&J vaccine after advisory panel vote
healthcaredive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcaredive.com Daily Mail and Mail on Sunday newspapers.
FDA, CDC lift pause on J&J Covid vaccinations Sara G. Miller and Erika Edwards © Provided by NBC News
The United States will resume use of the Johnson & Johnson Covid-19 vaccine, the Centers for Disease Control and Prevention and the Food and Drug Administration announced Friday, following an 11-day pause. With these actions the administration of Johnson & Johnson s Covid-19 vaccine can resume immediately, CDC director Dr. Rochelle Walensky said Friday evening during a media briefing.
The joint announcement came after a CDC advisory committee voted to recommend lifting the pause, but advised adding a warning about the increased risk of very rare but severe blood clots. The vote was 10 to 4, with one abstention for a conflict of interest.
Breaking News. Vaccinations with Johnson & Johnson s Covid-19 shot should resume, U.S. health regulators said after investigating rare blood-clotting cases, restoring a key tool for filling gaps in the mass vaccination campaign. To alert doctors and recipients to the condition that led to a pause in the vaccine s use last week, J&J and regulators plan to add language to the shot s label and fact sheets warning of the clotting condition risk. (More to Come) The following article will be updated momentarily A federal vaccine advisory committee Friday recommended that use of Johnson & Johnson s Covid-19 vaccine resume in the U.S., while J&J and regulators plan to add language to the product label warning of the potential for a rare blood-clot condition.
FDA, CDC lift pause on J&J COVID-19 vaccinations TODAY 3 hrs ago © Provided by TODAY
The United States will resume use of the Johnson & Johnson COVID-19 vaccine, the Centers for Disease Control and Prevention and the Food and Drug Administration announced Friday, following an 11-day pause. With these actions the administration of Johnson & Johnson s COVID-19 vaccine can resume immediately, CDC director Dr. Rochelle Walensky said Friday evening during a media briefing.
The joint announcement came after a CDC advisory committee voted to recommend lifting the pause, but advised adding a warning about the increased risk of very rare but severe blood clots. The vote was 10 to 4, with one abstention for a conflict of interest.
vimarsana © 2020. All Rights Reserved.